Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186342 · ClinicalTrials.gov registry record · NA
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 120
- Enrollment target
NCT00186342: Completed NA study, sponsored by Stanford University.
NCT00186342 is a NA study that has completed, run by Stanford University. The registered enrollment target is 120 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186342, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the tolerability and efficacy in treating patients aged 51-60 with acute leukemia and in treating myelodysplastic syndromes (MDS) or myeloproliferative disorders (MPD).
Interventions
- PROCEDURE ablative allogeneic hematopoietic cell transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 1992-09 |
| Est. Completion | 2009-01 |
| Phase | NA |
What the finished NCT00186342 record still lists
NCT00186342 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which ablative allogeneic hematopoietic cell transplantation is the first listed.
NCT00186342 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00186342 about?
NCT00186342 is a clinical study titled "Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies". The purpose of this study is to determine the tolerability and efficacy in treating patients aged 51-60 with acute leukemia and in treating myelodysplastic syndromes (MDS) or myeloproliferative disorders (MPD).
What is the current status of trial NCT00186342?
This trial is currently completed. It is a NA study. The enrollment target is 120 participants. The study started on 1992-09. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00186342?
The interventions under investigation include: ablative allogeneic hematopoietic cell transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00186342?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00186342's enrollment target sits among peer trials
120 762nd of 2000 higher than 1,198 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia